Answers are grounded in this paper and cite their sources.
Upper-limb bradykinesia, a cardinal symptom of Parkinson's disease (PD), significantly disrupts daily activities with slowness and reduced amplitude of voluntary movement. Current clinical assessments are episodic and subjective, and fail to capture real-world symptom fluctuations, while wearable systems suffer from low long-term adherence and vision-based solutions raise privacy concerns. We introduce mmBrady, the first contactless system that enables continuous, privacy-preserving estimation of upper-limb bradykinesia in daily environments using mmWave radar. To address core challenges including coarse clinical supervision, noisy superimposed signals, and heterogeneous daily activities, we propose three key modules: (1) a decoupled strategy using cross-modal dense supervision for kinematic extractors; (2) a hierarchical framework modeling spatial joint synergy to disentangle overlapping reflections; and (3) a semantic-aware multi-instance regressor that aggregates motion-stage-specific observations to distinguish pathological slowness from normal pauses. Evaluated on 42 PD patients across 8 real-world environments (clinic, nursing home, and homes), mmBrady achieves a high correlation of 0.73 and a low MAE of 1.59 with clinician-anchored MDS-UPDRS bradykinesia scores, which is even better than state-of-the-art single-wearable solutions but with no user burden. We will release the first contactless bradykinesia dataset to advance in-home neurological healthcare. We envision that mmBrady paves the way for longitudinal, low-burden PD monitoring to support timely medication adjustments and improve patient quality of life.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: